The award will support the development of diagnostics and analytical tools for childhood disease detection using tissue-based fluorescent in situ sequencing.
The company is currently in discussions with several investor groups and plans to use the funds to expand the reach of the test and prepare for FDA submission.
Intended for diagnosing active pulmonary tuberculosis, the test will use Cere's Nanotrap reagents for enriching target analytes for downstream analysis.
